Five-year clinical follow-up of prostatic cancer patients treated with fosfestrol and bromocriptine.

A five-year follow-up is presented of 123 patients with recently diagnosed prostatic cancer, confirmed histopathologically and treated with fosfestrol and bromocriptine. The combined treatment has been shown to prevent most of the complications and side effects of therapy, thus it is considered to be worthy of recommendation.